LY3202328

LY3202328 is an orally administered small molecule drug developed by Eli Lilly for the treatment of dyslipidemias and overweight/obesity. It acts as a selective inhibitor of diacylglycerol O-acyltransferase 2 (DGAT2), an enzyme involved in triglyceride synthesis. By inhibiting DGAT2, LY3202328 aims to reduce triglyceride levels and improve lipid profiles, potentially lowering cardiovascular risk. The drug has undergone Phase 1 clinical trials to evaluate its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy overweight participants and those with dyslipidemia[1][2][3][4][5][7]. No dose-limiting toxicities were observed in preclinical studies at high doses[5].